Tricida, Inc.

tricida.com

No Longer Reporting

The company has not filed an annual or quarterly report since its Q3 FY2022 10-Q, filed Nov 14, 2022. Its latest SEC filing is a EFFECT from Jun 16, 2023.

The sections below describe the company as of the FY2021 annual report.

What Did They Do?

Develops veverimer, an investigational oral drug designed to remove acid from the digestive tract, for patients with chronic kidney disease and metabolic acidosis.

How Were They Changing?

Since the FY2021 annual report

Latest quarter: Q3 FY2022, the three months to Sep 30, 2022

Net income: ▼ −35% (Loss); vs −$39.7M in Q3 FY2021

Jun 13, 2023 Liquidation plan took effect and common shares were canceled
May 25, 2023 Court confirmed the liquidation plan, canceling equity interests The plan provides distributions to certain creditor classes but none to holders of canceled equity interests.
Mar 15, 2023 Renibus completed its purchase of veverimer-related assets The sale covered intellectual property, inventory and related assets, with cash at closing and possible milestone payments.
Feb 24, 2023 Company agreed to sell assets to Renibus and Liquidity Services The proposed sales covered veverimer-related intellectual property and inventory, as well as laboratory equipment.

Broader treatment group The latest report adds patients with latent acidosis and normal bicarbonate as a possible future treatment group, beyond the earlier focus on patients with metabolic acidosis.